The new therapy proposed is based on a peptide analog of Cortistatin, efficacious as anti-inflammatory and modulator of the immune response and with an improved systemic half-life with respect tto the endogenous peptide.
Its therapeutic effect was tested in several preclinical models of inflammatory bowel disease and it was even more effective than current reference treatments used clinically for these patients, such as infliximab and mesalazine.
This work has been the result of a multidisciplinar collaboration between BCN Peptides and researchers from the Institut of Recerca Biomèdica – Barcelona and the Instituto de Parasitologíay Biomedicina López Neyra – CSIC Granada (IPBLN-CSIC).
The results have been published in Nature Communications.